Published in Biochem Pharmacol on April 13, 2007
Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol Rev (2010) 2.97
The Concise Guide to PHARMACOLOGY 2013/14: transporters. Br J Pharmacol (2013) 2.07
Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. Diabetes (2009) 1.72
Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenet Genomics (2009) 1.46
Metformin pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics (2012) 1.38
Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins. Mol Cancer Ther (2011) 1.35
Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study. Diabetes (2009) 1.34
Drug metabolism and transport during pregnancy: how does drug disposition change during pregnancy and what are the mechanisms that cause such changes? Drug Metab Dispos (2013) 1.27
Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat. Kidney Int (2014) 1.22
The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin. Clin Pharmacol Ther (2012) 1.19
Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function. Pharmacogenomics J (2009) 1.18
Functional characterization of liver enhancers that regulate drug-associated transporters. Clin Pharmacol Ther (2011) 1.14
Importance of the multidrug and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmacodynamics/toxicodynamics and pharmacogenomics. Br J Pharmacol (2011) 1.11
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling. J Med Chem (2013) 1.10
Pharmacokinetics of metformin during pregnancy. Drug Metab Dispos (2010) 1.09
Molecular determinants of ligand selectivity for the human multidrug and toxin extruder proteins MATE1 and MATE2-K. J Pharmacol Exp Ther (2012) 1.07
A common 5'-UTR variant in MATE2-K is associated with poor response to metformin. Clin Pharmacol Ther (2011) 1.07
Double-transfected MDCK cells expressing human OCT1/MATE1 or OCT2/MATE1: determinants of uptake and transcellular translocation of organic cations. Br J Pharmacol (2011) 1.02
Identification and characterization of novel polymorphisms in the basal promoter of the human transporter, MATE1. Pharmacogenet Genomics (2009) 1.00
An update on the pharmacogenomics of metformin: progress, problems and potential. Pharmacogenomics (2014) 0.97
How a microbial drug transporter became essential for crop cultivation on acid soils: aluminium tolerance conferred by the multidrug and toxic compound extrusion (MATE) family. Ann Bot (2010) 0.96
Organic cation transporter OCTs (SLC22) and MATEs (SLC47) in the human kidney. AAPS J (2013) 0.95
The role of drug transporters in the kidney: lessons from tenofovir. Front Pharmacol (2014) 0.91
Molecular mechanism of renal tubular secretion of the antimalarial drug chloroquine. Antimicrob Agents Chemother (2011) 0.91
Contribution of tumoral and host solute carriers to clinical drug response. Drug Resist Updat (2012) 0.90
Twelve transmembrane helices form the functional core of mammalian MATE1 (multidrug and toxin extruder 1) protein. J Biol Chem (2012) 0.88
Assessment of the role of renal organic anion transporters in drug-induced nephrotoxicity. Toxins (Basel) (2010) 0.88
Loss of multidrug and toxin extrusion 1 (MATE1) is associated with metformin-induced lactic acidosis. Br J Pharmacol (2012) 0.87
Human organic cation transporters 1 (SLC22A1), 2 (SLC22A2), and 3 (SLC22A3) as disposition pathways for fluoroquinolone antimicrobials. Antimicrob Agents Chemother (2013) 0.86
OCT2 and MATE1 provide bidirectional agmatine transport. Mol Pharm (2010) 0.85
Effect of gestational age on mRNA and protein expression of polyspecific organic cation transporters during pregnancy. Drug Metab Dispos (2013) 0.85
Multidrug transport protein norM from vibrio cholerae simultaneously couples to sodium- and proton-motive force. J Biol Chem (2014) 0.84
Substrate-dependent inhibition of human MATE1 by cationic ionic liquids. J Pharmacol Exp Ther (2013) 0.84
Interaction of H+ with the extracellular and intracellular aspects of hMATE1. Am J Physiol Renal Physiol (2011) 0.83
Measurement Error as Alternative Explanation for the Observation that CrCl/GFR Ratio is Higher at Lower GFR. Clin J Am Soc Nephrol (2016) 0.83
A simplified PBPK modeling approach for prediction of pharmacokinetics of four primarily renally excreted and CYP3A metabolized compounds during pregnancy. AAPS J (2013) 0.83
Genetic variation in drug transporters in ethnic populations. Clin Pharmacol Ther (2008) 0.82
Pharmacogenomics in type II diabetes mellitus management: Steps toward personalized medicine. Pharmgenomics Pers Med (2009) 0.81
Influences of organic cation transporter polymorphisms on the population pharmacokinetics of metformin in healthy subjects. AAPS J (2013) 0.81
Membrane transporters as mediators of Cisplatin effects and side effects. Scientifica (Cairo) (2012) 0.81
Prediction and validation of enzyme and transporter off-targets for metformin. J Pharmacokinet Pharmacodyn (2015) 0.80
Gene expression profiling of transporters in the solute carrier and ATP-binding cassette superfamilies in human eye substructures. Mol Pharm (2013) 0.80
Endocrine and metabolic regulation of renal drug transporters. J Biochem Mol Toxicol (2012) 0.80
Transporter-mediated drug-drug interactions with oral antidiabetic drugs. Pharmaceutics (2011) 0.79
Large contiguous gene deletions in Sjögren-Larsson syndrome. Mol Genet Metab (2011) 0.79
Moxifloxacin Is a Potent In Vitro Inhibitor of OCT- and MATE-Mediated Transport of Metformin and Ethambutol. Antimicrob Agents Chemother (2016) 0.78
Multiple Drug Transporters Are Involved in Renal Secretion of Entecavir. Antimicrob Agents Chemother (2016) 0.78
Characterization of MATE-type multidrug efflux pumps from Klebsiella pneumoniae MGH78578. PLoS One (2015) 0.78
Substrate-Dependent Inhibition of the Human Organic Cation Transporter OCT2: A Comparison of Metformin with Experimental Substrates. PLoS One (2015) 0.78
The pharmacogenetics of metformin. Diabetologia (2017) 0.77
Renal drug transporters and their significance in drug-drug interactions. Acta Pharm Sin B (2016) 0.77
Mechanistic models describing active renal reabsorption and secretion: a simulation-based study. AAPS J (2012) 0.77
Characterization of the inhibitory effects of N-butylpyridinium chloride and structurally related ionic liquids on organic cation transporters 1/2 and human toxic extrusion transporters 1/2-k in vitro and in vivo. Drug Metab Dispos (2011) 0.77
Combinatorial Pharmacophore Modeling of Multidrug and Toxin Extrusion Transporter 1 Inhibitors: a Theoretical Perspective for Understanding Multiple Inhibitory Mechanisms. Sci Rep (2015) 0.77
Distribution study of peplomycin in rat kidney revealed by immunocytochemistry using monoclonal antibodies. Histochem Cell Biol (2010) 0.76
Polyspecific organic cation transporters and their impact on drug intracellular levels and pharmacodynamics. Pharmacol Res (2016) 0.76
Novel minimal physiologically-based model for the prediction of passive tubular reabsorption and renal excretion clearance. Eur J Pharm Sci (2016) 0.76
Ischemia/Reperfusion-inducible protein modulates the function of organic cation transporter 1 and multidrug and toxin extrusion 1. Mol Pharm (2013) 0.75
Impact of Substrate-Dependent Inhibition on Renal Organic Cation Transporters hOCT2 and hMATE1/2-K-Mediated Drug Transport and Intracellular Accumulation. J Pharmacol Exp Ther (2016) 0.75
Organic and inorganic transporters of the testis: A review. Spermatogenesis (2015) 0.75
Pregnancy Increases the Renal Secretion of N1-methylnicotinamide, an Endogenous Probe for Renal Cation Transporters, in Patients Prescribed Metformin. Drug Metab Dispos (2017) 0.75
Genomic and expression analysis of a solute carrier protein (CcSLC25a5) gene from Cyprinus carpio Linnaeus. Springerplus (2013) 0.75
Urinary Dopamine as a Potential Index of the Transport Activity of Multidrug and Toxin Extrusion in the Kidney. Int J Mol Sci (2016) 0.75
The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin. Clin Pharmacokinet (2016) 0.75
The first characterization of multidrug and toxin extrusion (MATE/SLC47) proteins in zebrafish (Danio rerio). Sci Rep (2016) 0.75
Patient profiling in diabetes and role of canagliflozin. Pharmgenomics Pers Med (2014) 0.75
Pharmacogenetic variation of SLC47A1 gene and metformin response in type2 diabetes patients. Mol Biol Res Commun (2017) 0.75
Renal Drug Transporters and Drug Interactions. Clin Pharmacokinet (2017) 0.75
Physiologically Based Pharmacokinetic Modeling of Renally Cleared Drugs in Pregnant Women. Clin Pharmacokinet (2017) 0.75
Urinary Excretion of Tetrodotoxin Modeled in a Porcine Renal Proximal Tubule Epithelial Cell Line, LLC-PK₁. Mar Drugs (2017) 0.75
Xenobiotic transporters and kidney injury. Adv Drug Deliv Rev (2017) 0.75
Physiologically Based Pharmacokinetic Modelling and Prediction of Metformin Pharmacokinetics in Renal/Hepatic-Impaired Young Adults and Elderly Populations. Eur J Drug Metab Pharmacokinet (2017) 0.75
Mitochondrial genome variation in eastern Asia and the peopling of Japan. Genome Res (2004) 3.34
Laparoscopic radical nephroureterectomy: a multicenter analysis in Japan. Eur Urol (2009) 2.97
Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population. Nat Genet (2010) 2.92
Physical finding of nutcracker phenomenon. Kidney Int (2013) 2.60
Salt-sensitive hypertension in circadian clock-deficient Cry-null mice involves dysregulated adrenal Hsd3b6. Nat Med (2009) 2.30
Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient. Cancer Res (2005) 2.29
Cortical organization by the septin cytoskeleton is essential for structural and mechanical integrity of mammalian spermatozoa. Dev Cell (2005) 2.21
Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet (2005) 1.96
Efficacy of nondrug lifestyle measures for the treatment of nocturia. J Urol (2010) 1.94
Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J Am Soc Nephrol (2002) 1.85
An actin-binding protein Girdin regulates the motility of breast cancer cells. Cancer Res (2008) 1.82
UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. Int J Clin Oncol (2009) 1.82
Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol (2006) 1.80
XIST unmethylated DNA fragments in male-derived plasma as a tumour marker for testicular cancer. Lancet (2004) 1.76
Involvement of urinary bladder Connexin43 and the circadian clock in coordination of diurnal micturition rhythm. Nat Commun (2012) 1.74
SLCO4C1 transporter eliminates uremic toxins and attenuates hypertension and renal inflammation. J Am Soc Nephrol (2009) 1.70
Impact of IGF-I and CYP19 gene polymorphisms on the survival of patients with metastatic prostate cancer. J Clin Oncol (2006) 1.68
Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts. Liver Transpl (2012) 1.67
Outcome of different post-orchiectomy management for stage I seminoma: Japanese multi-institutional study including 425 patients. Int J Urol (2010) 1.65
Common variants at 11q12, 10q26 and 3p11.2 are associated with prostate cancer susceptibility in Japanese. Nat Genet (2012) 1.59
Laparoscopic partial nephrectomy using microwave tissue coagulator for small renal tumors: usefulness and complications. Eur Urol (2004) 1.55
Targeted disruption of the multidrug and toxin extrusion 1 (mate1) gene in mice reduces renal secretion of metformin. Mol Pharmacol (2009) 1.53
Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther (2006) 1.52
Involvement of vertebrate polkappa in Rad18-independent postreplication repair of UV damage. J Biol Chem (2002) 1.48
Regulation of connexin 43 by basic fibroblast growth factor in the bladder: transcriptional and behavioral implications. J Urol (2011) 1.48
Identification and comparative functional characterization of a new human riboflavin transporter hRFT3 expressed in the brain. J Nutr (2010) 1.47
Tacrolimus therapy as an alternative to thiopurines for maintaining remission in patients with refractory ulcerative colitis. J Clin Gastroenterol (2011) 1.47
Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother Pharmacol (2012) 1.43
Objective patterning of uroflowmetry curves in children with daytime and nighttime wetting. J Urol (2010) 1.41
A polymorphism of the POLG2 gene is genetically associated with the invasiveness of urinary bladder cancer in Japanese males. J Hum Genet (2011) 1.39
Identification and functional characterization of a novel human and rat riboflavin transporter, RFT1. Am J Physiol Cell Physiol (2008) 1.38
Is MIBG a substrate of P-glycoprotein? Eur J Nucl Med Mol Imaging (2006) 1.37
Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochem Pharmacol (2007) 1.35
Current status of endocrine therapy for prostate cancer in Japan analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP. Jpn J Clin Oncol (2007) 1.34
C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics (2002) 1.33
Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). Pharm Res (2007) 1.32
Eicosapentaenoic acid reduces the progression of carotid intima-media thickness in patients with type 2 diabetes. Atherosclerosis (2006) 1.31
Maternal riboflavin deficiency, resulting in transient neonatal-onset glutaric aciduria Type 2, is caused by a microdeletion in the riboflavin transporter gene GPR172B. Hum Mutat (2011) 1.31
Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat. Biochem Pharmacol (2005) 1.28
Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci U S A (2004) 1.27
Discrepancy between local and central pathological review of radical prostatectomy specimens. J Urol (2010) 1.24
Characteristics of patients with prostate cancer who have initially been treated by hormone therapy in Japan: J-CaP surveillance. Jpn J Clin Oncol (2004) 1.22
Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients. Clin Pharmacol Ther (2006) 1.20
Microarray-based identification of CUB-domain containing protein 1 as a potential prognostic marker in conventional renal cell carcinoma. J Cancer Res Clin Oncol (2008) 1.19
Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells. J Pharmacol Exp Ther (2009) 1.18
Secreted CXCL1 is a potential mediator and marker of the tumor invasion of bladder cancer. Clin Cancer Res (2008) 1.18
Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor protein. Am J Pathol (2006) 1.16
Diurnal rhythm of H+-peptide cotransporter in rat small intestine. Am J Physiol Gastrointest Liver Physiol (2002) 1.14
Collagenous matrices as release carriers of exogenous growth factors. Biomaterials (2004) 1.14
A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months. Jpn J Clin Oncol (2006) 1.13
Increased risk of bladder cancer associated with a glutathione peroxidase 1 codon 198 variant. J Urol (2004) 1.13
Clinical outcome of a large-scale multi-institutional retrospective study for locally advanced bladder cancer: a survey including 1131 patients treated during 1990-2000 in Japan. Eur Urol (2004) 1.13
The diurnal rhythm of the intestinal transporters SGLT1 and PEPT1 is regulated by the feeding conditions in rats. J Nutr (2004) 1.13
Molecular markers for bladder cancer screening, early diagnosis, and surveillance: the WHO/ICUD consensus. Urol Int (2014) 1.12
High 18F-fluorodeoxyglocose uptake in adrenal histoplasmosis; a case report. Eur Radiol (2005) 1.12
Development of a multiplex RNA urine test for the detection and stratification of transitional cell carcinoma of the bladder. Clin Cancer Res (2008) 1.11
Characterization of loss-of-inactive X in Klinefelter syndrome and female-derived cancer cells. Oncogene (2004) 1.11
Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation. Cancer Chemother Pharmacol (2011) 1.11
Septins as diagnostic markers for a subset of human asthenozoospermia. J Urol (2008) 1.09
The roles of supernumerical X chromosomes and XIST expression in testicular germ cell tumors. J Urol (2003) 1.08
Androgen receptor, Ki67, and p53 expression in radical prostatectomy specimens predict treatment failure in Japanese population. Urology (2005) 1.08
Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model. Cancer Res (2010) 1.08
Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. Pharmacogenet Genomics (2008) 1.08
Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. Biochem Pharmacol (2010) 1.07
Induction of smooth muscle cell-like phenotype in marrow-derived cells among regenerating urinary bladder smooth muscle cells. Am J Pathol (2005) 1.07
Relative frequency of underlying genetic causes for the development of UPD(14)pat-like phenotype. Eur J Hum Genet (2012) 1.07
Prospective evaluation of selection criteria for active surveillance in Japanese patients with stage T1cN0M0 prostate cancer. Jpn J Clin Oncol (2008) 1.06
Significance of organic cation transporter 3 (SLC22A3) expression for the cytotoxic effect of oxaliplatin in colorectal cancer. Drug Metab Dispos (2008) 1.06
STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma. J Clin Oncol (2007) 1.06
Association of genetic polymorphisms at 8q24 with the risk of prostate cancer in a Japanese population. Prostate (2008) 1.05
Organic cation transporter OCT/SLC22A and H(+)/organic cation antiporter MATE/SLC47A are key molecules for nephrotoxicity of platinum agents. Biochem Pharmacol (2010) 1.04
Polymorphisms in prostate-specific antigen (PSA) gene, risk of prostate cancer, and serum PSA levels in Japanese population. Cancer Lett (2003) 1.04
Feasibility and safety of laparoscopic and endoscopic cooperative surgery for gastric submucosal tumors, including esophagogastric junction tumors. Dig Endosc (2013) 1.02
The importance of integrin-linked kinase in the regulation of bladder cancer invasion. Int J Cancer (2011) 1.02
Insulin-like growth factor-binding protein-3 gene -202 A/C polymorphism is correlated with advanced disease status in prostate cancer. Cancer Res (2003) 1.01